| Entry |
|
| Name |
Epratuzumab (USAN/INN); Lymphocide (TN) |
| Efficacy |
Antineoplastic, Anti-CD22 antibody |
| Type |
Monoclonal antibody |
| Comment |
Treatment of non-Hodgkin's B-cell lymphomas
|
| Target |
|
| Pathway |
| hsa04514 | Cell adhesion molecule (CAM) interaction |
| hsa04662 | B cell receptor signaling pathway |
|
| Brite |
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD22 (SIGLEC2)
D04036 Epratuzumab (USAN/INN)
|
| Other DBs |
|
| LinkDB |
|